 CAMBRIDGE, Mass., May 25, 2021 GLOBE NEWSWIRE -- Vor Biopharma Nasdaq: VOR or the Company, a cell therapy company pioneering engineered hematopoietic stem cell eHSC therapies combined with targeted therapies for the treatment of cancer, today announced that the Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vors Chief Financial Officer, are scheduled to present at the following conferences: 